Showing results (171-180 of 251) with videos related to
Sort By:
Pageof 26
Frontiers in Immunology|March 13, 2024
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-αElizabeth A Spencer, Marla C Dubinsky, Michael A Kamm, et al.Inflammatory Bowel Diseases|November 5, 2025
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's DiseaseMarla C Dubinsky, Geert D'Haens, Olivier Dewit, et al.Current Medical Research and Opinion|July 10, 2025
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) surveyMarla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, et al.Inflammatory Bowel Diseases|October 12, 2004
A pilot study of adalimumab in infliximab-allergic patientsAdrienne Youdim, Eric A Vasiliauskas, Stephan R Targan, et al.Inflammatory Bowel Diseases|September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic AcidAndres Yarur, Peter Irving, Britta Siegmund, et al.Crohn'S & Colitis 360|February 13, 2023
Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative ColitisMarla C Dubinsky, Remo Panaccione, James D Lewis, et al.Crohn'S & Colitis 360|February 13, 2023
Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBDBenjamin Click, Edward L Barnes, Benjamin L Cohen, et al.Inflammatory Bowel Diseases|April 23, 2016
TNFRSF1B Is Associated with ANCA in IBDDalin Li, Mark S Silverberg, Talin Haritunians, et al.Inflammatory Bowel Diseases|March 11, 2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behaviorGary R Lichtenstein, Stephan R Targan, Marla C Dubinsky, et al.Journal of Crohn'S & Colitis|May 16, 2019
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel DiseaseRyan C Ungaro, Andres Yarur, Jacqueline Jossen, et al.Pageof 26